For example, ICI182,780 (fulvestrant) is an established FDA-approved drug for clinical use in hormone receptor-positive metastatic breast cancer (73), but few trials have explored the efficacy of ICI182,780 for treating endometrial cancer. The gene discussed is NR4A1; the disease is endometrial cancer.